Log In
Print this Print this

Tysabri, natalizumab

Also known as: AN100226 (formerly Antegren)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionHumanized mAb against integrin alpha(4)
Molecular Target Integrin alpha(4) (VLA-4 ) (CD49D)
Mechanism of ActionBinds integrin alpha(4); Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today